We are live on ! Find out more
AMYT

Amryt Pharma

Delisted

AMYT was delisted on the 11th of April, 2023.

62 hedge funds and large institutions have $316M invested in Amryt Pharma in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

472% more capital inflows, than outflows

Capital inflows: $18.6M | Capital outflows: $3.26M

143% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 7

3.13% more ownership

Funds ownership: 67.94% → 71.07% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

3% less funds holding

Funds holding: 64 → 62 (-2)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $6K

Holders
62
Holders Change
-2
Holders Change %
-3.13%
% of All Funds
1.06%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
10
Increased
17
Reduced
7
Closed
10
Calls
–
Puts
$6K
Net Calls
-$6K
Net Calls Change
-$246K

AMYT Hedge Fund Activity: Q3 2022 in Review

62 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Amryt Pharma (AMYT) for Q3 2022, worth a combined $316M — up 0.62% from $314M a quarter earlier.

Fund positioning in AMYT was balanced in Q3 2022: 10 funds opened new positions, 10 closed out, 17 added to existing stakes and 7 trimmed.

The largest buyer was Man Group, opening a new position worth an estimated $9.8M. The largest seller was Nantahala Capital Management, cutting an estimated $933K.

  • 62 institutional investors held Amryt Pharma (AMYT) as of Q3 2022, down from 64 in Q2 2022.
  • Funds reported $316M of Amryt Pharma stock for Q3 2022, up 0.62% quarter-over-quarter.
  • 10 funds opened new Amryt Pharma positions in Q3 2022 and 10 closed out, a net change of 0 holders.
  • The largest Amryt Pharma buyer in Q3 2022 was Man Group, an estimated $9.8M added.
  • The largest Amryt Pharma seller in Q3 2022 was Nantahala Capital Management, an estimated $933K sold.

Based on aggregated 13F filings for Q3 2022.